Page last updated: 2024-11-08

anisomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID253602
CHEMBL ID423192
CHEBI ID338412
SCHEMBL ID2270183
MeSH IDM0001251

Synonyms (118)

Synonym
smr000471874
MLS001066392 ,
anisomycin from streptomyces griseolus
CBIOL_002064
(-)-anisomycin
2-p-methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine
antibiotic pa-106
3,4-pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2r-(2-alpha,3-alpha,4-beta))-
ai3-50846
nsc 76712
1,4,5-trideoxy-1,4-imino-5-(p-methoxyphenyl)-d-xylo-pentitol 3-acetate
3,4-pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2r-(2alpha,3alpha,4beta))-
brn 0020705
einecs 245-269-7
2-(p-methoxybenzyl)-3,4-pyrrolidinediol 3-acetate
HMS3267L11
BRD-K91370081-001-04-6
A-7940
KBIO1_000855
DIVK1C_000855
NCI60_041689
SDCCGMLS-0066810.P001
SPECTRUM_001534
SPECTRUM5_001495
BSPBIO_001436
QTL1_000009
IDI1_000855
BIO1_000350
BIO1_001328
BIO1_000839
upjohn 204t3
6185-rbk-10
3, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, [2s-(2.alpha.,3.alpha.,4.beta.)]-
3, 2-(p-methoxybenzyl)-, 3-acetate, (2s,3r,4r)-
nsc-76712
PRESTWICK3_000412
BPBIO1_000402
BSPBIO_000364
ANM ,
AB00513833
22862-76-6
anisomycin
[(2r,3s,4s)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate
flagecidin
NSC76712 ,
3,4-pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2r,3s,4s)-
(-) anisomycin
anisomycin from streptomyces griseolus, >=98% (hplc), solid
2-(p-methoxybenzyl)-3,4-pyrrolidinediol-3-acetate
NCGC00025097-02
KBIOGR_001076
KBIOSS_002014
KBIO2_002014
KBIO2_007150
KBIO2_004582
SPBIO_000624
SPECTRUM2_000632
SPECTRUM4_000748
NINDS_000855
SPECTRUM1503906
NCGC00025097-03
NCGC00025097-04
(2r,3s,4s)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate
CHEBI:338412 ,
gnf-pf-4549 ,
CHEMBL423192
DB07374
TCMDC-125504 ,
HMS502K17
HMS1922K06
HMS2096C06
anisomycin,streptomyces griseolus
HMS2231E05
CCG-39185
unii-6c74ym2ngi
(2r,3s,4s)-2-(p-methoxybenzyl)-3,4-pyrrolidinediol 3-acetate
(2r,3s,4s)-2-((4-methoxyphenyl)methyl)-3,4-pyrrolidinediol 3-acetate
(2r,3s,4s)-2-(p-methoxyphenylmethyl)-3-acetoxy-4-hydroxypyrrolidine
6c74ym2ngi ,
3,4-pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2r,3s,4s)-
5-21-05-00523 (beilstein handbook reference)
AKOS015916532
anisomycin [mi]
anisomycin, (-)-
YKJYKKNCCRKFSL-RDBSUJKOSA-N
HY-18982
anisomycin, antibiotic for culture media use only
CS-4981
SCHEMBL2270183
(2r,3s,4s)-2-[(4-methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate
acetic acid [(2r,3s,4s)-4-hydroxy-2-p-anisyl-pyrrolidin-3-yl] ester
cid_253602
acetic acid [(2r,3s,4s)-4-hydroxy-2-[(4-methoxyphenyl)methyl]-3-pyrrolidinyl] ester
bdbm63919
[(2r,3s,4s)-2-[(4-methoxyphenyl)methyl]-4-oxidanyl-pyrrolidin-3-yl] ethanoate
AC-35125
(2r,3s,4s)-2-(4-methoxybenzyl)-3,4-pyrrolidinediol 3-acetate
DTXSID5040966
mfcd00077650
SR-01000597397-1
sr-01000597397
SR-01000597397-3
(2r,3s,4s)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl acetate
Q378498
HB2239
HMS3678L15
AS-44380
11023-48-6
wuningmeisu c
3,4-pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate,(2r,3s,4s)-
HMS3414L17
[[4-[2-[[(3-ethyl-2,5-dihydro-4-methyl-2-oxo-1h-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulfonyl]carbamicacidethylester
BRD-K91370081-001-17-8
flagecidin;wuningmeisu c
A927918
(2r,3s,4s)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-ylacetate
21497-40-5
rel-(2r,3s,4s)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate

Research Excerpts

Overview

Anisomycin is a pyrrolidine antibiotic isolated from Streptomyces griseolus. It is a candidate drug for parasite, cancer, immunosuppression, and mental disease.

ExcerptReferenceRelevance
"Anisomycin is a candidate drug for parasite, cancer, immunosuppression, and mental disease."( Anisomycin induces hair cell death and blocks supporting cell proliferation in zebrafish lateral line neuromast.
Fan, C; Qin, Y; Wang, J; Yuan, X, 2021
)
2.79
"Anisomycin is a pyrrolidine antibiotic isolated from Streptomyces griseolus. "( In vivo toxicological evaluation of Anisomycin.
Chen, D; Di, J; Liu, J; Tang, Z; Xing, F; Yu, C; Yu, Y, 2012
)
2.1
"Anisomycin acts as a mixed noncompetitive inhibitor."( Kinetics of inhibition of rabbit reticulocyte peptidyltransferase by anisomycin and sparsomycin.
Coutsogeorgopoulos, C; Ioannou, M; Synetos, D, 1998
)
1.26

Effects

Anisomycin has been widely used as an inhibitor of protein synthesis in studies on learning and memory. It has been given into the cerebral ventricles of rabbits.

ExcerptReferenceRelevance
"Anisomycin has been shown to inhibit tumour cell growth."( Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/PDGFRA axis.
Huang, Y; Liu, T; Ni, Z; Pan, H; Xiong, Y; Ye, W; Yicheng, S, 2019
)
2.68
"Anisomycin has not previously been characterized as antifibrotic, thus, this is a novel finding of the study."( A cell-based screening assay to identify pharmaceutical compounds that enhance the regenerative quality of corneal repair.
Bauskar, A; Fini, ME; Gordon, GM; Itakura, T; Jeong, S; LaGier, AJ; Patel, N; Ponchel, C,
)
0.85
"Anisomycin has been widely used as an inhibitor of protein synthesis in studies on learning and memory as well as synaptic plasticity. "( Anisomycin treatment paradigm affects duration of long-term potentiation in slices of the amygdala.
Hess, G; Kaczmarek, L; Okulski, P, 2002
)
3.2
"1. Anisomycin has been given into the cerebral ventricles of rabbits. "( Further observations on the suppression of fever in rabbits by intracerebral action of anisomycin.
Cranston, WI; Hellon, RF; Townsend, Y, 1982
)
1.11
"Anisomycin has been shown to stabilize ribosome initiation complexes containing messenger RNA and met-tRNAf met to high salt conditions. "( Inhibition of 80S initiation complex formation by infection with poliovirus.
Ehrenfeld, E; Manis, S, 1979
)
1.7

Actions

Anisomycin did not cause aggregation of intact or saponin-permeabilised platelets. It was shown to cause a significant degree of amnesia for the escape component as well as the avoidance component of the learning. Both an isomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase.

ExcerptReferenceRelevance
"Anisomycin is known to inhibit eukaryotic protein synthesis and has been established as an antibiotic and anticancer drug. "( Anisomycin protects against sepsis by attenuating IκB kinase-dependent NF-κB activation and inflammatory gene expression.
Chung, SW; Lee, SJ; Min, JK; Park, GL; Park, M; Park, YJ, 2021
)
3.51
"Anisomycin was used to activate P38, and p-P38, p-CREB, and MMP13 were evaluated by immunofluorescence and Western blot analysis."( Activation of the P38/CREB/MMP13 axis is associated with osteoarthritis.
Fang, X; Ji, B; Ma, Y; Shi, P; Wang, H, 2019
)
1.24
"The anisomycin-induced increase in Förster resonance energy transfer was abolished by the TAK1 inhibitor (5z)-7-oxozeaenol."( Live imaging of transforming growth factor-β activated kinase 1 activation in Lewis lung carcinoma 3LL cells implanted into syngeneic mice and treated with polyinosinic:polycytidylic acid.
Baba, A; Kamioka, Y; Matsuda, M; Seya, T; Shime, H; Takakura, K; Takaoka, S, 2016
)
0.92
"Anisomycin is known to inhibit protein synthesis and induce ribotoxic stress."( Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin.
Hashimoto, T; Jin, X; Kakehi, Y; Kanematsu, A; Li, Y; Nakanishi, Y; Nojima, M; Suzuki, T; Togo, Y; Wang, J; Wu, X; Yamada, Y; Yamamoto, S, 2017
)
1.39
"Anisomycin is known to inhibit protein synthesis and induce ribotoxic stress. "( Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1.
Kim, S; Kwon, TK; Lee, TJ; Min, KJ; Park, JW; Park, WK; Seo, BR, 2013
)
3.28
"As anisomycin can activate Jun amino terminal kinases, as well as p38 MAP kinase, it is possible that other MAP kinases, such as Jun amino terminal kinases, also contribute to the increase in gene levels."( Regulation of corticotropin-releasing factor receptor type 2beta mRNA by mitogen-activated protein kinases in aortic smooth muscle cells.
Hanada, K; Kageyama, K; Suda, T, 2005
)
0.84
"As anisomycin did not cause acetylation of nucleosome core histones, the present work focuses on the molecular mechanisms mediating the HDAC-independent induction of IEG c-fos by anisomycin in E1A + cHa-ras-transformed fibroblasts."( Anisomycin abrogates repression of protooncogene c-fos transcription in E1A + cHa-ras-transformed cells through activation of MEK/ERK kinase cascade.
Amanzholov, RA; Kukushkin, AN; Pospelov, VA; Svetlikova, SB, 2008
)
2.3
"Anisomycin can inhibit the reaction of lymphocytes and prolong the survival period of the grafts in skin transplantation effectively. "( [Effect of anisomycin on allogeneic skin transplantation in mice].
Chen, D; Chen, L; DI, JF; Xing, FY, 2008
)
2.18
"Anisomycin did not produce positive or negative behavioral effects at 24 hr when administered 15 min prior to and again 3 hr after propylene glycol, suggesting that the behavioral effects of anisomycin appear to be related to selective blockade of progesterone action."( Sequential inhibition of sexual receptivity by progesterone is prevented by a protein synthesis inhibitor and is not causally related to decreased levels of hypothalamic progestin receptors in the female rat.
McEwen, BS; Parsons, B, 1981
)
0.98
"Anisomycin did not cause the aggregation of either intact or saponin-permeabilised platelets."( Anisomycin does not activate p38MAPK in human platelets.
McNicol, A; Pampolina, C, 1999
)
2.47
"Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase."( Differential effects of stress stimuli on a JNK-inactivating phosphatase.
Ashworth, A; Theodosiou, A, 2002
)
0.77
"Anisomycin was shown to cause a significant degree of amnesia for the escape component as well as the avoidance component of the learning."( Effects of protein synthesis inhibition on memory for active avoidance training.
Bennett, EL; Flood, JF; Orme, AE; Rosenzweig, MR, 1975
)
0.98

Treatment

Anisomycin treatment lowered retinal translation rates, accelerated retinal degeneration in rd16 mice, and initiated cell death in the retinas of C57BL/6J mice. Anisomyin treatment of human SMA fibroblasts and sciatic nerve ligation in SMA mice provoked robust p-c-Jun expression.

ExcerptReferenceRelevance
"Anisomycin treatment lowered retinal translation rates, accelerated retinal degeneration in rd16 mice, and initiated cell death in the retinas of C57BL/6J mice. "( Role of Translational Attenuation in Inherited Retinal Degeneration.
Boulton, ME; Gorbatyuk, MS; Gorbatyuk, OS; Hu, Y; Nyankerh, CNA; Qi, X; Sonenberg, N; Starr, CR, 2019
)
1.96
"Anisomycin treatment of human SMA fibroblasts and sciatic nerve ligation in SMA mice provoked robust phosphorylated-c-Jun (p-c-Jun) expression indicating that SMN-deficiency does not prevent activation of the stress-induced JNK-c-Jun signaling pathway."( Motor neuron loss in SMA is not associated with somal stress-activated JNK/c-Jun signaling.
Chen, KS; d'Ydewalle, C; Griswold-Prenner, I; Kong, L; Park, JH; Pilato, CM; Sumner, CJ; Valdivia, D, 2019
)
1.24
"Anisomycin-treated neurons also showed significant decreases in firing frequencies and spike amplitudes, and showed increases in spike width across spike trains, without changes in spike threshold."( The amnestic agent anisomycin disrupts intrinsic membrane properties of hippocampal neurons via a loss of cellular energetics.
Dickson, CT; Hamilton, TJ; LeBlancq, MJ; Lemieux, H; Nargang, F; Scavuzzo, CJ, 2019
)
1.56
"Anisomycin treatment induced thick and irregular linear staining for ZO-1, while anisomycin plus SP600125 treatment induced zipper-like staining for ZO-1."( p38 Mitogen-activated protein kinase and c-Jun NH2-terminal protein kinase regulate the accumulation of a tight junction protein, ZO-1, in cell-cell contacts in HaCaT cells.
Anan, H; Iida, H; Inai, T; Kitagawa, N; Minakami, M, 2015
)
1.14
"Anisomycin treatment resulted in an increase in Nox2 protein and the phosphorylation of Nox2, which was blocked by inhibition of p38."( Disruption of Nox2 and TNFRp55/p75 eliminates cardioprotection induced by anisomycin.
Guo, TL; Liu, JT; Zhang, L; Zhao, TC, 2012
)
1.33
"Anisomycin treatment led to the down-regulation of Bcl-2 expression at the transcriptional level, and the over-expression of Bcl-2 inhibited the apoptosis induced by the combination treatment of anisomycin and TRAIL."( Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1.
Kim, S; Kwon, TK; Lee, TJ; Min, KJ; Park, JW; Park, WK; Seo, BR, 2013
)
2.55
"Anisomycin treatment led to a strong activation of the stress kinases p38 kinases and the jun kinases, that was not sufficient for the activation of caspase-3 which required much higher concentrations."( Formation of caspase-3 complexes and fragmentation of caspase-12 during anisomycin-induced apoptosis in AKR-2B cells without aggregation of Apaf-1.
Hoppe, J; Hoppe, V; Kagerhuber, U; Kilic, M; Sachinidis, A, 2002
)
1.27
"Anisomycin-treated rats showed no savings in the rate of re-learning of extinction, consistent with amnesia for extinction training."( Consolidation of fear extinction requires protein synthesis in the medial prefrontal cortex.
Ge, H; Peña de Ortiz, S; Quirk, GJ; Ren, K; Santini, E, 2004
)
1.04
"Anisomycin treatment of chromaffin cells potentiated the forskolin-induced increase in tyrosine hydroxylase activity by 50%."( Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells.
Bobrovskaya, L; Dickson, PW; Dunkley, PR, 2004
)
1.04
"Anisomycin pretreatment strongly activated p38 MAP kinase in fMLP-stimulated cells, accompanied by greatly increased superoxide production, suggesting that p38 MAP kinase determines the extent of the fMLP-stimulated NADPH oxidase activity."( Involvement of p38 MAP kinase in not only activation of the phagocyte NADPH oxidase induced by formyl-methionyl-leucyl-phenylalanine but also determination of the extent of the activity.
Kuribayashi, F; Nakamura, M; Sakamoto, K; Takeshige, K, 2006
)
1.06
"Anisomycin treatments alone produced no effects on acute cocaine-induced locomotion."( Application of a protein synthesis inhibitor into the ventral tegmental area, but not the nucleus accumbens, prevents behavioral sensitization to cocaine.
Sorg, BA; Ulibarri, C, 1995
)
1.01
"Anisomycin treatment activated NF kappa B in the WT cells as early as 0.5 hr after treatment but did not activate NF kappa B in the Y8 cells."( p53-independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines.
Cory, JG; He, AW,
)
1.2
"Anisomycin (1 microM) treatment mimics the cytokine-induced enhancement of arachidonic acid production and activates the p38 MAPK pathway, but does not activate the NF-kappaB pathway."( Inflammatory cytokines enhance muscarinic-mediated arachidonic acid release through p38 mitogen-activated protein kinase in A2058 cells.
Felder, CC; Mark, RJ; Ogden, AM; Segal, JA; Wood, MW, 2000
)
1.03
"Anisomycin treatment of cultured adipocytes for 5 h produced an 8-fold stimulation of hexose transport but no increase in the content of glucose transporters in the plasma membrane fraction as measured by protein immunoblot analysis."( Activation of cell surface glucose transporters measured by photoaffinity labeling of insulin-sensitive 3T3-L1 adipocytes.
Clancy, BM; Czech, MP; Harrison, SA; Pessino, A, 1992
)
1
"Treating with anisomycin (ANS), an activator of p38, the phosphorylation and nuclear translocation of CREB are both promoted, while the transcription of CA9 is repressed."( CREB is a key negative regulator of carbonic anhydrase IX (CA9) in gastric cancer.
Cheng, Z; Li, F; Li, J; Liu, F; Wang, G; Zhang, H, 2015
)
0.76
"Treatment with anisomycin, a potent activator of JNK, before IgE sensitization significantly suppressed antigen-induced degranulation."( Down-modulation of antigen-induced activation of murine cultured mast cells sensitized with a highly cytokinergic IgE clone.
Furuta, K; Hyodo, N; Ichikawa, A; Kurimune, Y; Natsuhara, M; Sakanaka, M; Tanaka, S; Yamada, K, 2016
)
0.77
"The treatment of anisomycin prolonged the survival of the transplanted skin and depressed the delayed type hypersensitivity development and the T-cell response in the skin-transplanted mice."( Anisomycin inhibits the behaviors of T cells and the allogeneic skin transplantation in mice.
Chen, D; Chen, G; Chen, L; Chen, Z; Di, J; Fan, Z; Fang, Z; Guo, Z; Hao, W; Li, Y; Liu, J; Liu, N; Long, Y; Mao, C; Pan, S; Teng, Z; Wang, J; Xing, F; Yu, Z; Zeng, S,
)
1.9
"Co-treatment with anisomycin increased activation of caspases and cleavage of the anti-apoptotic protein Livin, leading to formation of truncated p30-Livin α and p28-Livin β proteins with potential pro-apoptotic functions."( Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.
Emilsen, E; Engesæter, B; Flørenes, VA; Mælandsmo, GM; Rosnes, AK; Slipicevic, A; Stakkestad, Ø; Øy, GF, 2013
)
1.13
"Treatment with anisomycin or daunorubicin in the presence of ZVAD increased expression of FasL mRNA and protein but did not alter expression of Fas mRNA or protein."( Apoptosis of bovine ovarian surface epithelial cells by Fas antigen/Fas ligand signaling.
Cowan, RG; Harman, RM; Margalit, KA; Quirk, SM, 2005
)
0.67
"Treatment with anisomycin elicited comparable activation of p38 MAPK and HSP27 in both young and aged hearts, coupled with a pronounced and equivalent cardioprotection in the two groups (73+/-3% and 77+/-2%, respectively), an effect abolished by the p38 MAPK inhibitor, SB203580."( Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection.
Gross, ER; Gross, GJ; Headrick, JP; Peart, JN, 2007
)
0.68
"Treatment with anisomycin also decreased synthesis of [3H]-norepinephrine (NE)."( The effects of Cycloheximide and Anisomycin on monoamine synthesis in a brain synaptosome preparation.
Carr, LA; Schweri, MM, 1982
)
0.89
"Treatment with anisomycin and cycloheximide also potentiated 0.1 microM 3-MC-induced coumarin 7-hydroxylase activity, induced c-fos and jun-D mRNA expression, and activated AP-1-dependent gene transcription in the hepatocytes."( Okadaic acid potentiates 3-methylcholanthrene-induced CYP2A8 gene expression in primary cultures of Syrian hamster hepatocytes: possible involvement of activator protein-1.
Fukuhara, M; Kurose, K; Tohkin, M, 1996
)
0.63
"Rats treated with anisomycin alone also showed significant increases in striatal 5-HT and 5-HIAA concentrations which were somewhat higher on the side of the ICV infusions."( The protein synthesis inhibitor, anisomycin, causes exacerbation of the iminodipropionitrile-induced spasmodic dyskinetic syndrome in rats.
Cadet, JL; Fahn, S; Jackson-Lewis, V; Katz, M; Stennett, R, 1989
)
0.88

Toxicity

ExcerptReferenceRelevance
"Taste memories are amongst the most important kinds of memories, as adequate identification of safe and toxic edibles will determine the subject's survival."( Medial temporal lobe structures participate differentially in consolidation of safe and aversive taste memories.
Balderas, I; Bermudez-Rattoni, F; De la Cruz, V; Rodriguez-Ortiz, CJ, 2008
)
0.35
" A useful model for studying memory formation is gustatory memory, a type of memory in which a novel taste may become either safe by not being followed by negative consequences (attenuation of neophobia, AN), or aversive by being followed by post-digestive malaise (conditioned taste aversion, CTA)."( Safe taste memory consolidation is disrupted by a protein synthesis inhibitor in the nucleus accumbens shell.
Bermúdez-Rattoni, F; Guzmán-Ramos, K; Pedroza-Llinás, R; Ramírez-Lugo, L; Zavala-Vega, S, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The insulin-like growth factor-binding proteins (IGFBPs) are a family of six proteins that modulate the biological activity of IGF-I and IGF-II and determine their bioavailability to tissues."( Cycloheximide stabilizes insulin-like growth factor-binding protein-1 (IGFBP-1) mRNA and inhibits IGFBP-1 transcription in H4-II-E rat hepatoma cells.
Brown, DR; Ooi, GT; Rechler, MM; Suh, DS; Tseng, LY, 1993
)
0.29

Dosage Studied

Anisomycin dosing regimen failed to affect subsequent expression of cocaine-CPP when additional cocaine conditioning trial was used in the absence of additional saline trial. Animals injected with an isomycin whose testing began 1 day after training demonstrated partial recovery irrespective of drug dosage level.

ExcerptRelevanceReference
" Animals injected with anisomycin whose testing began 1 day after training demonstrated partial recovery irrespective of drug dosage level."( Recovery as a function of the degree of amnesia due to protein synthesis inhibition.
Davis, HP; Rosenzweig, MR, 1978
)
0.57
" The dose-response curves of the steroids differed, however, in that cyproterone acetate produced a greater mean stimulation of the enzyme at concentrations less than approximately 25 muM, whereas, at higher concentrations, cyproterone was the more effective inducer."( Cyproterone-mediated stimulation of delta-aminolevulinic acid synthetase in chick embryo liver cells.
Gidari, AS; Lane, SE; Levere, RD, 1976
)
0.26
" Both phenotypic classes of PC12 cells respond to aurintricarboxylic acid with similar dose-response characteristics."( Nerve growth factor withdrawal-induced cell death in neuronal PC12 cells resembles that in sympathetic neurons.
Green, SH; Mesner, PW; Winters, TR, 1992
)
0.28
"Moderate improvement of cognitive function has been reported in many clinical studies of Hydergine (HYD) but in only a few controlled dose-response studies in animals."( Hydergine enhances memory in mice.
Cherkin, A; Flood, JF; Smith, GE, 1985
)
0.27
" This apparent plateau of CM activity appears to be a function of production and/or release of CF, rather than a saturation effect on plated cells, since dose-response curves for dilutions of CM are approximately linear regardless of the number of ganglia used for conditioning."( Nerve growth-promoting factor produced in culture media conditioned by specific CNS tissues of the snail Helisoma.
Barker, DL; Bodnar, DA; Kater, SB; Wong, RG, 1984
)
0.27
" Dose-response analysis showed that, in A549 cells, anisomycin strongly induced uPAR and PAI-1 mRNA at concentrations that did not cause complete inhibition of protein synthesis, whereas cycloheximide induced these transcripts in a dose-dependent manner only at concentrations sufficient to inhibit total protein synthesis by >90%."( Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines.
Lund, LR, 1996
)
0.54
" Dose-response experiments showed that precisely the same concentration of a specific drug was required to inhibit protein synthesis and to either stimulate or inhibit RNA replication."( Translating ribosomes inhibit poliovirus negative-strand RNA synthesis.
Barton, DJ; Flanegan, JB; Morasco, BJ, 1999
)
0.3
" Dose-response and time course studies of the effects of heat shock and anisomycin treatment showed a close correlation of the activation of JNK and hyperphosphorylation of HSF1."( JNK phosphorylates the HSF1 transcriptional activation domain: role of JNK in the regulation of the heat shock response.
Liu, AY; Park, J, 2001
)
0.54
" However, a similar anisomycin dosing regimen failed to affect subsequent expression of cocaine-CPP when additional cocaine conditioning trial was used in the absence of additional saline trial."( Systemic treatment with protein synthesis inhibitors attenuates the expression of cocaine memory.
Cheng, LY; Cherng, CG; Fan, HY; Lin, LC; Tsai, CJ; Yang, FY; Yu, L, 2010
)
0.68
" The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."( Spiroindolones, a potent compound class for the treatment of malaria.
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010
)
0.36
" PROAST benchmark dose (BMD) modeling was used to characterize the resulting dose-response curves."( 3Rs-friendly approach to exogenous metabolic activation that supports high-throughput genetic toxicology testing.
Bemis, JC; Bryce, SM; Cyr, A; Dertinger, SD; Hall, N; Tian, S; Zeise, K, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
antiparasitic agentA substance used to treat or prevent parasitic infections.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
protein synthesis inhibitorA compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monohydroxypyrrolidine
organonitrogen heterocyclic antibiotic
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Monoamine transport01

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency39.81070.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency0.02790.004110.890331.5287AID624247; AID624248; AID624249; AID624251; AID624252; AID686934
TDP1 proteinHomo sapiens (human)Potency0.14580.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency0.13650.00527.809829.0929AID588855; AID720534; AID720536; AID720537
67.9K proteinVaccinia virusPotency0.66900.00018.4406100.0000AID720579; AID720580
hepatitis C virus polyproteinPotency7.04560.444510.437124.9988AID720575
IDH1Homo sapiens (human)Potency0.04610.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency3.71180.00419.984825.9290AID504444; AID720524
gemininHomo sapiens (human)Potency0.57420.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency0.01260.125912.234435.4813AID1458
Alpha-synucleinHomo sapiens (human)Potency28.18380.56239.398525.1189AID652106
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
caspase recruitment domain family, member 15Homo sapiens (human)IC50 (µMol)49.75100.62154.05046.6330AID651553
receptor-interacting serine/threonine-protein kinase 2 isoform 1Homo sapiens (human)IC50 (µMol)49.75100.62154.05046.6330AID651553
Glucose transporterLeishmania mexicanaIC50 (µMol)0.22500.08102.30676.7450AID1207598
Hexose transporter 1 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.32600.09002.22205.8850AID1207597
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)0.32100.00492.99549.9920AID1207599
Beta lactamase (plasmid)Pseudomonas aeruginosaIC50 (µMol)49.75100.70915.05497.7510AID651552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BCL-2-RELATED PROTEIN A1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)0.24300.160024.4900236.5000AID2382
heat shock protein 90Candida albicansEC50 (µMol)1.48100.12006.485533.8530AID2423
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)0.09650.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)0.09650.00304.57559.8200AID1804127
bcl-2-like protein 11 isoform 1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)0.09650.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)0.09650.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.09650.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)0.09650.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.09650.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)0.09650.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.09650.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)0.09650.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BCL-2-RELATED PROTEIN A1Homo sapiens (human)AC50150.33970.920095.9176498.8000AID449754; AID449755; AID449757
PAX8Homo sapiens (human)AC500.26000.04885.435469.1700AID687027
Hsf1 proteinMus musculus (house mouse)AC500.36100.171030.8718167.9780AID493083; AID493085; AID588827
Bcl-2-like protein 11Homo sapiens (human)AC5099.93009.841085.8882287.1000AID449757
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (194)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 11Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 11Homo sapiens (human)
B cell homeostasisBcl-2-like protein 11Homo sapiens (human)
kidney developmentBcl-2-like protein 11Homo sapiens (human)
myeloid cell homeostasisBcl-2-like protein 11Homo sapiens (human)
apoptotic processBcl-2-like protein 11Homo sapiens (human)
cell-matrix adhesionBcl-2-like protein 11Homo sapiens (human)
spermatogenesisBcl-2-like protein 11Homo sapiens (human)
male gonad developmentBcl-2-like protein 11Homo sapiens (human)
post-embryonic developmentBcl-2-like protein 11Homo sapiens (human)
mammary gland developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of protein-containing complex assemblyBcl-2-like protein 11Homo sapiens (human)
response to endoplasmic reticulum stressBcl-2-like protein 11Homo sapiens (human)
tube formationBcl-2-like protein 11Homo sapiens (human)
odontogenesis of dentin-containing toothBcl-2-like protein 11Homo sapiens (human)
regulation of apoptotic processBcl-2-like protein 11Homo sapiens (human)
T cell homeostasisBcl-2-like protein 11Homo sapiens (human)
positive regulation of apoptotic processBcl-2-like protein 11Homo sapiens (human)
positive regulation of neuron apoptotic processBcl-2-like protein 11Homo sapiens (human)
ear developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of cell cycleBcl-2-like protein 11Homo sapiens (human)
regulation of organ growthBcl-2-like protein 11Homo sapiens (human)
developmental pigmentationBcl-2-like protein 11Homo sapiens (human)
regulation of developmental pigmentationBcl-2-like protein 11Homo sapiens (human)
spleen developmentBcl-2-like protein 11Homo sapiens (human)
thymus developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of T cell apoptotic processBcl-2-like protein 11Homo sapiens (human)
thymocyte apoptotic processBcl-2-like protein 11Homo sapiens (human)
cellular response to glucocorticoid stimulusBcl-2-like protein 11Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBcl-2-like protein 11Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 11Homo sapiens (human)
positive regulation of mitochondrial membrane permeability involved in apoptotic processBcl-2-like protein 11Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 11Homo sapiens (human)
apoptotic process involved in embryonic digit morphogenesisBcl-2-like protein 11Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseBcl-2-like protein 11Homo sapiens (human)
positive regulation of fibroblast apoptotic processBcl-2-like protein 11Homo sapiens (human)
meiosis IBcl-2-like protein 11Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (67)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingBcl-2-like protein 11Homo sapiens (human)
microtubule bindingBcl-2-like protein 11Homo sapiens (human)
protein kinase bindingBcl-2-like protein 11Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (65)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 11Homo sapiens (human)
cytosolBcl-2-like protein 11Homo sapiens (human)
endomembrane systemBcl-2-like protein 11Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 11Homo sapiens (human)
mitochondrionBcl-2-like protein 11Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (94)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID67520Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID251932Percent inhibition against MurPath in Staphylococcus aureus cell walls at the concentration of 25 uM; Not tested2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID510926Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID50859Antibacterial activity against Clostridium novyi, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID211150Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID202860Antifungal activity against Saccharomyces cerevisiae, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID211134Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas foetus1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID211151Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID41121Antibacterial activity against Bacteroides fragilis, activity expressed as minimum inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID211137Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas foetus1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID211138Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas foetus1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID401589Inhibition of protein biosynthesis in mouse Krebs cells assessed as renilla luciferase activity at 10 uM after 1 hr by translation assay relative to control2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID401564Inhibition of protein synthesis in human HeLa cells at 10 uM by [35S]methionine metabolic labeling study2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID70072Antifungal activity against Epidermophyton floccosum, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID211149Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID160375Antibacterial activity against Propionibacterium acnes, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID47571Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone (mm, diameter); QA is questionable activity1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID510945Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone3 within 1 hrs by [35S]Met/Cys incorporation assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID30563Antibacterial activity against Actinomyces israelii, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID67518Antiprotozoal activity measured as the conc for <25% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID510944Inhibition of protein synthesis in NITD609-resistant Plasmodium falciparum Dd2 Clone1 within 1 hrs by [35S]Met/Cys incorporation assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID214096Antifungal activity against Trichophyton mentagrophytes, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID210260Antibacterial activity against Streptococcus pyogenes C, activity expressed as inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID401587Inhibition of protein biosynthesis in mouse Krebs cells assessed as firefly luciferase activity at 10 uM after 1 hr by translation assay relative to control2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID510929Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID44956Antifungal activity against Candida albicans, activity expressed as minimum inhibitory concentration (ug/mL)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID244807Minimum inhibitory concentration against Staphylococcus aureus2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID211152Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas vaginalis1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID214101Antifungal activity against Trichophyton mentagrophytes, activity expressed as minimum inhibitory concentration (ug/mL).1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID202866Antifungal activity against Saccharomyces cerevisiae, activity expressed as minimum inhibitory concentration (ug/mL).1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID401569Inhibition of translation in human HeLa cells at 10 uM by 35S-methionine metabolic labeling study2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID67380Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID247794Inhibitory concentration required to produce cytotoxicity against HEK293 cells2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID251790Percent inhibition against MraY/MurG in Staphylococcus aureus cell walls at 25 uM; Not tested2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID506759Inhibition of 25 nM rapamycin-mediated cytostatic effect in yeast BY4742 at sub-lethal concentration after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID211132Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas foetus; ND denotes no data1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID70074Antifungal activity against Epidermophyton floccosum, activity expressed as minimum inhibitory concentration (ug/mL)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID1431378Antiviral activity against Hepatitis B virus subtype adw2 infected in human HuH7 cells assessed as inhibition of viral DNA replication at 10 uM after 2 days by RT-PCR method2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID47570Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone (mm, diameter)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID67515Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID732530Activation of p38MAPK in mouse RAW264.7 cells assessed as phosphorylation at Thr180/Tyr182 at 5 uM after 30 mins by Western blotting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A novel semisynthetic flavonoid 7-O-galloyltaxifolin upregulates heme oxygenase-1 in RAW264.7 cells via MAPK/Nrf2 pathway.
AID67509Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID67517Antiprotozoal activity measured as the conc for 95-25% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID510928Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID401566Inhibition of protein synthesis in human HeLa cells assessed as translation at 10 uM by [35S]methionine metabolic labeling study2004Journal of natural products, May, Volume: 67, Issue:5
A new antimalarial quassinoid from Simaba orinocensis.
AID67381Antiprotozoal activity measured as the conc for <25% inhibition of Entamoeba histolytica1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID510939Antimalarial activity against Plasmodium falciparum assessed as [35S]Met/Cys incorporation by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID67379Antiprotozoal activity measured as the conc for 95-25% inhibition of Entamoeba histolytica; ND denotes no data1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID381436Increase of U50488-induced JNK phosphorylation in untransfected HEK293 cells at 50 uM after 15 mins2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
AID251695Percent inhibition against efflux-deficient strain of Candida albicans at 15.5 uM2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1129018Inhibition of translation in rabbit reticulocyte lysates using SP6 RNA polymerase at 10 uM by FF/HCV/Ren reporter gene assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Synthesis of the antiproliferative agent hippuristanol and its analogues from hydrocortisone via Hg(II)-catalyzed spiroketalization: structure-activity relationship.
AID510927Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID211135Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas foetus1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID211147Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis; ND denotes not data1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Structure-activity relationships of synthetic antibiotic analogues of anisomycin.
AID251743Percent inhibition against RG-1 mutant strain of Candida albicans at 15.5 uM; Not tested2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin.
AID492453Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Antimalarials from nature.
AID381430Increase of JNK phosphorylation in U50488 treated untransfected HEK293 cells at 100 uM after 15 mins2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,312)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990234 (17.84)18.7374
1990's249 (18.98)18.2507
2000's468 (35.67)29.6817
2010's297 (22.64)24.3611
2020's64 (4.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.25 (24.57)
Research Supply Index7.21 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index68.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews17 (1.25%)6.00%
Case Studies1 (0.07%)4.05%
Observational0 (0.00%)0.25%
Other1,339 (98.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]